iBankCoin
Home / Zenhunter (page 32)

Zenhunter

Don't pay dollar to keep 2 cents when wrong. Cut your losses quickly. Trade what you see, not what you think.

Is $CUR leading the stem cell miracle?

Price action seems to suggest it.

Take a look at the daily chart below:

CUR_daily

Today price has finally broken up to the upside.

However, take a look at the weekly chart below:

cur_weekly

There is still another hurdle for price action to take out and that is the resistance established back in June and July of last year.  And if today momentum continues on this week, it will be like cutting butter with a hot knife.

Fundamentally speaking, I’ll let you read this article and ponder.

Yes, I’ve already placed my bet on this one.

My 2 cents.

Comments »

Is $INO the ultimate breakout play?

I’m betting that it is.

Let’s start with the weekly chart:

INO_weekly

Last week breakout bar had massive volume of 23 million shares; while the inverted hammer candlestick of last week was not convincingly bullish; this week up bar clear up last week indecision.  Today is only the 2nd day of the week and volume has already exceeded half of last week.

Below is the daily chart:

INO_daily

The uptrend looks more straight forward than the weekly chart since you are not looking at the inverted hammer candlestick bar.

The monthly chart below gives you an idea of the possible resistances and potential of future price action.

INO_monthly

Did you see how price action has finally broken out of a 2 years consolidation period (from mid-2011 to now)?  Remember the old saying, “the longer the consolidation period, the more powerful is the breakout?”  Does this old saying apply to $INO?

I’ve placed my bet that $INO can be the mother-of-all biotech speculation with a high reward/risk ratio at this level.

Fundamentally speaking, $INO is pushing synthetic DNA vaccines into the new frontier of biotech discovery.  $INO has come a long way in researching on this field and 2013-2014 may be the years of acknowledgement that this science actually works (or not).  So far, the data are encouraging; however, the caveat is that these data are from preclinical and Phase I results.  Between now and 2014, results from various Phase I to Phase II trials will either propel $INO to much higher price or send it back to oblivion.

The risk is high and so is the reward.  If there is such a thing as mother-of-all biotech speculation, this is it.  And this is definitely not for the faint of heart.

My 2 cents.

Comments »

Is $ATRS ready for a Cup and handle breakout?

I believe so.

Let’s start with the weekly chart:

ATRS_weekly

Did you see the general long-term uptrend?  However, I like to see price action takes out the Jan 11th high and close above that to confirm a continuation of uptrend after the correction from July of last year.

Now, let’s take a look at the daily chart:

ATRS_daily

Did you see the handle?  While the handle is still lower than the rim of the cup, I still think the pattern is valid.

Fundamentally speaking, who doesn’t like a needle-less injection?

$ATRS announced acceptance of the OTREXUP New Drug Application (NDA) by the FDA.  And the FDA has assigned a prescription drug user fee act (PDUFA) target date of October 14, 2013.

The speculation of an approval could fuel a run from here.

I bought $ATRS today looking to see a breakout from the cup and handle pattern in the next few days.

My 2 cents.

Comments »

Can $LYV keep the party going?

What do young people do when they don’t want to stay at home?  Go to the movie?  What do you do after two hours?  It comes to my attention that these young people like to go to concerts- lot of them.  And this is where $LYV (Live Nation Entertainment) comes in.

With more and more children come of age to become teenagers and 20+ young adults looking to get out of the house, concert businesses are expanding.  You can see the trend picking on $LYV from the monthly chart below.

LYV_monthly

Keep an eye on the resistance at $16.90 – $18 level; if price action can take out these long-time resistance, price may not look back.

Needless to say, I bought some $LYV and added more today with the expectation that price action would break out of the $17 -$18 resistance.  Time will tell.

My 2 cents.

Comments »

The wakening of $LRAD

For those who has followed my blog, you know that $LRAD is my second largest position in my portfolio.  After months of waiting, I believe my patience is finally paying off.

Today price action reflect a big up day with high volume.  Since I’m holding this for long term, I like to think that today action is just the beginning.  Future catalysts for more higher prices can be the “winning” of contract order from US Army, foreign sales to China (don’t you think China will need this technology to address their massive population?) and other countries who will soon find usefulness for LRAD technology.

The multi-charts below give you a better feel for the overall picture.

LRAD_multichart

My 2 cents.

Comments »

Is $DNDN finding its bottom?

I like to bet that it is by buying some today.

Take a look at the weekly chart below.

DNDN_multi

Did you see how the price level find support at $3.81 area for the last five weeks?  I also like the long-tail 15m chart where price has traded back up to $4.00 level.  A daily doji bar for now could also be a positive sign for a neutral ground before heading back up (or down).

A stop below $3.80 for a stop will yield a good low risk trade with high reward if this is the bottom.

My 2 cents.

Comments »

Something is cooking at $PACB

Can you see the daily subtle buying interest in $PACB for the last 3 weeks?  The monthly, weekly, daily, hourly, and 15m charts all reflect an upward trend.  I fathom that something must be cooking inside $PACB that is smelling good; therefore, I’ve bought position in $PACB today even though price has been up quite a bit recently.

See below multi-charts window:

PACB_multi

My 2 cents.

Comments »

Zen seeks $YNDX for info

I bought $YNDX for a bounce to take out previous high of $29.48.  I believe $YNDX is the Russian $BIDU in the making.

Take a look at the weekly chart below:

YNDX_weekly

All it takes is for $YNDX to take out the recent high and it would automatically break out of the resistance that has been around since October 2011.  Did you see the April 26 weekly bar?  The one with the bad ass long green bar?  That was the tell tale sign.  I may sit on this one for long-term.

My 2 cents.

Comments »

Zen sees $TSLA has been recharged

Ok, one has to recognize strength when one sees it in action.  Despite a heavy 200+ down day on the DOW, $TSLA has managed to bounce back from the low and peek its head above water.  Normally, in my book, a stock with a parabolic run “should” correct severely on a big DOW down day.  Nope, not $TSLA.

Take a look at today beautiful “T” shape candlestick bar in the daily chart below:

TSLA_daily

I bought June 21st $90 call option to go long.

My 2 cents.

Comments »

Zen hunts $BIOD for better insulin

Truth be told, I got shaken out of $MNKD from $5+ awhile back and missed the run to $7+.  I would not want to chase $MNKD at this level; but I see an opportunity with $BIOD which market cap is only 3% of $MNKD ($60 mil vs $2 bil).  Ok, $MNKD insulin delivery system is probably more preferably than needle but $BIOD new phase II mealtime insulin is supposed to be better than currently available mealtime insulin, so they say.  Top line result from phase II trial is expected to release around September this year; so I like to see a summer run to a possible $10+.

I build a position today @ low $4.00 to take advantage of today correction.

This is a super low float company so I expect a lot of volatility; so it is not for the faint of heart.

Take a look at the chart below:

BIOD_daily

The only technical support I see here is the 38.2% retracement which today low has bounced off from.

Btw, I can’t help but feel that the money flow has recently been flowing toward anything related to diabetes medicine.  My position on $TINY is getting a good rally probably due to its recent announcement that one of its start-up investment, Metabolon, has launched a diagnostic Test based on Metabolon’s Quantose(TM) Insulin Resistance Markers.

I’m afraid with the amount of sugar our nation is consuming, diabetes health issue is becoming more prominent.

My 2 cents.

Comments »